1. Home
  2. MDWD vs EP Comparison

MDWD vs EP Comparison

Compare MDWD & EP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • EP
  • Stock Information
  • Founded
  • MDWD 2000
  • EP 1983
  • Country
  • MDWD Israel
  • EP United States
  • Employees
  • MDWD N/A
  • EP N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • EP Oil & Gas Production
  • Sector
  • MDWD Health Care
  • EP Energy
  • Exchange
  • MDWD Nasdaq
  • EP Nasdaq
  • Market Cap
  • MDWD 184.8M
  • EP 248.9M
  • IPO Year
  • MDWD 2014
  • EP N/A
  • Fundamental
  • Price
  • MDWD $19.02
  • EP $6.51
  • Analyst Decision
  • MDWD Strong Buy
  • EP
  • Analyst Count
  • MDWD 1
  • EP 0
  • Target Price
  • MDWD $25.00
  • EP N/A
  • AVG Volume (30 Days)
  • MDWD 61.7K
  • EP 31.6K
  • Earning Date
  • MDWD 11-26-2024
  • EP 11-14-2024
  • Dividend Yield
  • MDWD N/A
  • EP N/A
  • EPS Growth
  • MDWD N/A
  • EP N/A
  • EPS
  • MDWD N/A
  • EP N/A
  • Revenue
  • MDWD $19,720,000.00
  • EP $43,254,386.00
  • Revenue This Year
  • MDWD $10.37
  • EP N/A
  • Revenue Next Year
  • MDWD $26.36
  • EP N/A
  • P/E Ratio
  • MDWD N/A
  • EP N/A
  • Revenue Growth
  • MDWD N/A
  • EP 10.97
  • 52 Week Low
  • MDWD $11.04
  • EP $4.06
  • 52 Week High
  • MDWD $24.00
  • EP $8.46
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 61.79
  • EP 44.48
  • Support Level
  • MDWD $15.80
  • EP $6.43
  • Resistance Level
  • MDWD $18.25
  • EP $8.12
  • Average True Range (ATR)
  • MDWD 0.88
  • EP 0.38
  • MACD
  • MDWD 0.07
  • EP -0.13
  • Stochastic Oscillator
  • MDWD 95.27
  • EP 4.73

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About EP Empire Petroleum Corporation

Empire Petroleum Corp is a conventional oil and natural gas producer with a main focus in the US onshore. The company possesses long-life, mature, producing assets with slow decline profiles in the Permian Basin, Bakken region and central Gulf Coast region, in the states of New Mexico, North Dakota, Montana, Louisiana and Texas. It has production from operated and non-operated wells in Lea County in New Mexico, Bottineau, Renville, Burke, and McKenzie Counties in North Dakota, Richland County in Montana, St. Landry, Beauregard Parishes in Louisiana and Houston, Leon and Madison Counties in Texas.

Share on Social Networks: